In vivo evaluation of risperidone-SAIB in situ system as a sustained release delivery system in rats

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 68, Issue 2, 2008, Pages 422-429

  Lu, Yaxin ^a   Tang, Xing ^a   Cui, Yue ^a   Zhang, Yu ^a   Qin, Feng ^a   Lu, Xiumei ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

In situ system; In vivo pharmacokinetics; Risperidone; SAIB; Sustained release delivery system

Indexed keywords

ALCOHOL; POLYLACTIC ACID; RISPERIDONE; SUCROSE ACETATE ISOBUTYRATE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG METABOLISM; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SUSTAINED DRUG RELEASE;

ANIMALS; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; DELAYED-ACTION PREPARATIONS; MALE; PARTICLE SIZE; RATS; RATS, WISTAR; RISPERIDONE; SENSITIVITY AND SPECIFICITY;

EID: 37849015813     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2007.05.016     Document Type: Article

References (26)

1. Bhanji N.H., Chouinard G., and Margolese H.C. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur. Neuropsychopharmacol. 14 (2004) 87-92
2. Jansen P.A.J., Niemegeers C.J.E., Awouters F., Schellekens K.H.L., Megens A.A.H.P., and Meert T.F. Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J. Pharmacol. Exp. Ther. 244 (1988) 685-693
3. Leysen J.E., Gommeren W., Eeens A., de Chaffoy de Courdells D., Stoof J.C., and Janssen P.A. Biochemical profiles of risperidone, a new antipsychotic. J. Pharmacol. Exp. Ther. 244 (1988) 661-670
4. Claus A., Bollen J., De Cuyper H., Eneman M., Malfroid M., Peuskens J., et al. Risperidone versus haloperidol in the treatment of chromic schizophrenia inpatians: multicenter double-blind comparative study. Acta Psychiatr. Scand. 85 (1992) 295-305
5. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W., et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13 (1993) 25-40
6. Grant S., and Fitton A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 48 (1994) 253-273
7. Markowitz J.S., Brown C.S., and Moore T.R. Atypical antipsychotics. Part I: pharmacology, pharmacokinetics, and efficacy. Ann. Pharmacother. 33 (1999) 73-85
8. Hatefi A., and Amsden B. Biodegradable injectable in situ forming drug delivery systems. J. Control. Release 80 (2002) 9-28
9. Matschke C., Isele U., Van H.P., and Fahr A. Sustained release injectables formed in situ and their potential use for veterinary products. J. Control. Release 85 (2002) 1-15
10. Wang L., Venkatraman S., and Kleiner L. Drug release from injectable depots: two different in vitro mechanisms. J. Control. Release 99 (2004) 207-216
11. Packhaeuser C.B., Schnieders J., Oster C.G., and Kissel T. In situ forming parenteral drug delivery systems: an overview. Eur. J. Pharm. Biopharm. 58 (2004) 445-455
12. Qiao M., Chen D., Ma X., and Liu Y. Injectable biodegradable temperature-responsive PLGA-PEG-PLGA copolymers: synthesis and effect of copolymer composition on the drug release from the copolymer-based hydrogels. Int. J. Pharm. 294 (2005) 103-112
13. Kang F., and Singh J. In vitro release of insulin and biocompatibility of in situ forming gel systems. Int. J. Pharm. 304 (2005) 83-90
14. Smith D.A., and Tipton A.J. A novel parenteral delivery system. Pharm. Res. 13 9 (1996) 300
15. Darling S., Okumu F.W., Sullivan S.A., Tipton A.J., and Clealand J.L. Extended release of human growth hormone suspended in Saber™ formulation design and in vitro assessment. Proc. Int. Symp. Control. Rel. Bioact. Mater. 28 (2001) 474-475
16. Johnson C.A., Thompson D.L.J., Sullivan S.A., Gibson J.W., Tipton A.J., Simon B.W., and Burns P.J. Biodegradable delivery systems for estradiol: comparison between poly(DL-lactide) microspheres and the SABER delivery system. Proc. Int. Symp. Control. Release Bioact. Mater. 26 (1999) 74-75
17. Aravagiri M., and Marder S.R. Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry. J. Mass Spectrom. 35 (2000) 718-724
18. Mannens G., Huang M.L., Meuldermans W., Hendrickx J., Woestenborghs R., and Heyknats J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab. Dispos. 21 (1993) 1134-1141
19. Meuldermans W., Hendrickx J., Mannens G., Lavrijsen K., Janssen C., Bracke J., Le J.L., Lauwers W., and Heykants J. The metabolism and excretion of risperidone after oral administration in rats and dogs. Drug Metab. Dispos. 22 (1994) 129-138
20. Aravagiri M., Marder S.R., Ames D., and Wirshing W.C. Plasma concentration of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry 31 (1998) 102-109
21. Huang M.L., Van P.A., Woestenborghs R., De C.R., Heykants J., Janssen A.A.I., Zylicz Z., Visscher H.W., and Jonkman J.H.G. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin. Pharmacol. Ther. 54 3 (1993) 257-268
22. Megens A.A.H.P., Awouters F.H.L., Schotte A., Meert T.F., Dugovic C., Niemegeers C.J.E., and Le ysen J.E. Survey on the pharmacodynamies of the new antipsychotic risperidone. Psychopharmacology 114 (1994) 9-23
23. Okumu F.W., Dao L.N., Fielder P.J., Dybdal N., Brooks D., Sane S., and Cleland J.L. Sustained delivery of human growth hormone from a novel gel system: SABER. Biomaterials 23 (2002) 4353-4358
24. Wheatley M.A., Chang M., Park E., and Langer R. Coated alginate microspheres: factors influencing the controlled delivery of macromolecules. J. Appl. Polym. Sci. 43 (1991) 2123-2125
25. Hirano K., Ichihashi T., and Yamad H. Studies on the absorption of practically water-insoluble drugs following injection. I: intramuscular absorption from water immiscible oil solutions in rats. Chem. Pharm. Bull. 2 (1981) 519-531
26. Eerdekens M., Van Hove I., Remmerie B., and Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophrenia Res. 70 (2004) 91-100